Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Krill oil reduces plasma triacylglycerol level and improves related lipoprotein particle concentration, fatty acid composition and redox status in healthy young adults - a pilot study

Open access

Abstract

BACKGROUND: Lipid abnormalities, enhanced inflammation and oxidative stress seem to represent a vicious circle in atherogenesis, and therapeutic options directed against these processes seems like a reasonable approach in the management of atherosclerotic disorders. Krill oil (RIMFROST Sublime®) is a phospholipid-rich oil with eicosapentaenoic acid (EPA): docosahexaenoic acid (DHA) ratio of 1.8:1. In this pilot study we determined if krill oil could favourable affect plasma lipid parameters and parameters involved in the initiation and progression of atherosclerosis. METHODS: The study was conducted as a 28 days intervention study examining effect-parameters of dietary supplementation with krill oil (832.5 mg EPA and DHA per day). 17 healthy volunteers in the age group 18-36 (mean age 23 ± 4 years) participated. Plasma lipids, lipoprotein particle sizes, fatty acid composition in plasma and red blood cells (RBCs), plasma cytokines, antioxidant capacity, acylcarntines, carnitine, choline, betaine, and trimethylamine-N-oxide (TMAO) were measured before and after supplementation. RESULTS: Plasma triacylglycerol (TAG) and large very-low density lipoprotein (VLDL) & chylomicron particle concentrations decreased after 28 days of krill oil intake. A significant reduction in the TAG/HDL cholesterol resulted. Krill oil supplementation decreased n-6/n-3 polyunsaturated fatty acids (PUFA) ratio both in plasma and RBCs. This was due to increased EPA, DHA and docosapentaenoic acid (DPA) and reduced amount of arachidonic acid (AA). The increase of n-3 fatty acids and wt % of EPA and DHA in RBC was of smaller magnitude than found in plasma. Krill oil intake increased the antioxidant capacity, double bond index (DBI) and the fatty acid anti-inflammatory index. The plasma atherogenicity index remained constant whereas the thrombogenicity index decreased. Plasma choline, betaine and the carnitine precursor, γ-butyrobetaine were increased after krill oil supplementation whereas the TMAO and carnitine concentrations remained unchanged. CONCLUSION: Krill oil consumption is considered health beneficial as it decreases cardiovascular disease risk parameters through effects on plasma TAGs, lipoprotein particles, fatty acid profile, redox status and possible inflammation. Noteworthy, no adverse effects on plasma levels of TMAO and carnitine were found.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12944-015-0162-7

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Plasma lipid profile after krill oil intake. Plasma TAG (a), correlation between plasma TAG and large VLDL & CM concentration (b), correlation between plasma TAG and medium VLDL & CM concentration (c), plasma total cholesterol (d), plasma HDL-cholesterol (e), plasma LDL-cholesterol (f), plasma non-HDL-cholesterol (g), plasma HDL-cholesterol/LDL-cholesterol ratio (h), plasma TAG/HDL-cholesterol (i), plasma total cholesterol/HDL-cholesterol (j), plasma PL (k), plasma NEFA (l). Values from all 17 participants are shown. Significant difference was determined by Wilcoxon signed-rank test (*p < 0.05, **p < 0.01). Correlation coefficients (R) were determined by Spearman correlation, and linear regressions are shown
Fig. 1 Plasma lipid profile after krill oil intake. Plasma TAG (a), correlation between plasma TAG and large VLDL & CM concentration (b), correlation between plasma TAG and medium VLDL & CM concentration (c), plasma total cholesterol (d), plasma HDL-cholesterol (e), plasma LDL-cholesterol (f), plasma non-HDL-cholesterol (g), plasma HDL-cholesterol/LDL-cholesterol ratio (h), plasma TAG/HDL-cholesterol (i), plasma total cholesterol/HDL-cholesterol (j), plasma PL (k), plasma NEFA (l). Values from all 17 participants are shown. Significant difference was determined by Wilcoxon signed-rank test (*p < 0.05, **p < 0.01). Correlation coefficients (R) were determined by Spearman correlation, and linear regressions are shownCC BY · PubMed Central
Fig. 2 Fatty acid composition in plasma and RBC after krill oil supplementation. Plasma n-6/n-3 ratio (a), RBC n-6/n-3 ratio (b), plasma wt % of EPA + DHA (c), RBC wt % of EPA + DHA (omega-3 index)(d), plasma double bond index (e), RBC double bond index (f), plasma anti-inflammatory index (g), RBC anti-inflammatory index (h), plasma trombogenicity index (i), plasma atherogenicity index (j). Values are given as means with standard deviations (n = 17). Significant difference was determined by Wilcoxon signed-rank test (***p < 0.001)
Fig. 2 Fatty acid composition in plasma and RBC after krill oil supplementation. Plasma n-6/n-3 ratio (a), RBC n-6/n-3 ratio (b), plasma wt % of EPA + DHA (c), RBC wt % of EPA + DHA (omega-3 index)(d), plasma double bond index (e), RBC double bond index (f), plasma anti-inflammatory index (g), RBC anti-inflammatory index (h), plasma trombogenicity index (i), plasma atherogenicity index (j). Values are given as means with standard deviations (n = 17). Significant difference was determined by Wilcoxon signed-rank test (***p < 0.001)CC BY · PubMed Central
Fig. 3 Antioxidant capacity (AOC) status after krill oil intake. Plasma level of AOC (a), correlation between plasma EPA concentration and AOC (b), correlation between EPA concentration in RBC and AOC (c), correlation between DBI and AOC in RBC (d). AOC is given as mean with standard deviation (n = 14). Significant difference was determined by Wilcoxon signed-rank test (**p < 0.01). Correlation coefficients (R) were determined by Spearman correlation, and linear regressions are shown
Fig. 3 Antioxidant capacity (AOC) status after krill oil intake. Plasma level of AOC (a), correlation between plasma EPA concentration and AOC (b), correlation between EPA concentration in RBC and AOC (c), correlation between DBI and AOC in RBC (d). AOC is given as mean with standard deviation (n = 14). Significant difference was determined by Wilcoxon signed-rank test (**p < 0.01). Correlation coefficients (R) were determined by Spearman correlation, and linear regressions are shownCC BY · PubMed Central
Fig. 4 Plasma TMAO, carnitine, and carnitine precursors after krill oil intake. Plasma levels of TMAO (a), choline (b), betaine (c), carnitine (d), γ-butyrobetaine (e), and trimethyllysine (f). Values are given as means with standard deviation (n = 17). Significant difference was determined by Wilcoxon signed-rank test (*p < 0.05, **p < 0.01, ***p < 0.001)
Fig. 4 Plasma TMAO, carnitine, and carnitine precursors after krill oil intake. Plasma levels of TMAO (a), choline (b), betaine (c), carnitine (d), γ-butyrobetaine (e), and trimethyllysine (f). Values are given as means with standard deviation (n = 17). Significant difference was determined by Wilcoxon signed-rank test (*p < 0.05, **p < 0.01, ***p < 0.001)CC BY · PubMed Central
Fig. 5 Plasma acylcarnitines after krill oil intake. Plasma levels of octanoylcarnitine (a), palmitoylcarnitine (b), acetylcarnitine (c), iso-/L-valerylcarnitine (d), and propionylcarnitine (e). Values are given as means with standard deviation (n = 17). Significant difference was determined by Wilcoxon signed-rank test (**p < 0.01, ***p < 0.001)
Fig. 5 Plasma acylcarnitines after krill oil intake. Plasma levels of octanoylcarnitine (a), palmitoylcarnitine (b), acetylcarnitine (c), iso-/L-valerylcarnitine (d), and propionylcarnitine (e). Values are given as means with standard deviation (n = 17). Significant difference was determined by Wilcoxon signed-rank test (**p < 0.01, ***p < 0.001)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 3

  1. World Health Organization (WHO). Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk. 2007.
  2. European Food Safety Authority (EFSA) Panel on Dietetic Products NaAN. Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA). In: Book Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA). 2010.
  3. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Choline. In: Book Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B-6, Vitamin B12, Panthothenic Acid, Biotin, and Choline. Washington (National Acedemies Press); 1998. p. 390–422.

Cited by

See all 56

Metadata

Authors
Berge, R. K., Ramsvik, M. S., Bohov, P., Svardal, A., Nordrehaug, J. E., Rostrup, E., Bruheim, I., & Bjørndal, B.
Affiliations
  • Haukeland University Hospital (NO)
  • Rimfrost (Norway) (NO)
  • University of Bergen (NO)
Corresponding author
Bjørndal, Bodil
Venue
Lipids in Health and Disease
Published
2015-12
Volume
14
Issue
1
Pages
163-163
ISSN
1476-511X (ISSN-L)
OpenAlex
W2219729937
Cited by
51
References
56
Citations by year
2026: 2 · 2025: 7 · 2024: 5 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 6 · 2018: 7 · 2017: 2 · 2016: 1
FWCI
3.21
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Lipids in Health and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
Funders
  • Bergens Forskningsstiftelse
  • Rimfrost AS, Fosnavaag, Norway
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Physical Sciences › Chemistry › Organic Chemistry › Edible Oils Quality and Analysis
  • Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
Keywords
krill oil, eicosapentaenoic acid, docosahexaenoic acid, triglycerides, lipoprotein particle size, VLDL, chylomicrons, plasma fatty acid composition, red blood cell fatty acids, n-6/n-3 ratio, arachidonic acid, docosapentaenoic acid, oxidative stress, antioxidant capacity, atherogenicity index, thrombogenicity index, trimethylamine N-oxide, choline, betaine, L-carnitine
MeSH terms
Adolescent, Adult, Animals, Betaine, Carnitine, Choline, Chylomicrons, Dietary Fats, Unsaturated, Docosahexaenoic Acids, Erythrocytes, Fatty Acids, Unsaturated, Female, Humans, Lipoproteins, VLDL, Male, Methylamines, Particle Size, Pilot Projects, Triglycerides, Eicosapentaenoic Acid, Cytokines, Euphausiacea, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Krill oil reduces plasma triacylglycerol level and improves related lipoprotein particle concentration, fatty acid composition and redox status in healthy young adults - a pilot study. https://app.cochat.ai/papers/10.1186/s12944-015-0162-7
The paper
Berge, R. K., Ramsvik, M. S., Bohov, P., Svardal, A., Nordrehaug, J. E., Rostrup, E., Bruheim, I., & Bjørndal, B. (2015). Krill oil reduces plasma triacylglycerol level and improves related lipoprotein particle concentration, fatty acid composition and redox status in healthy young adults - a pilot study. Lipids in Health and Disease. https://doi.org/10.1186/s12944-015-0162-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.